TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30183438
Drug: Existing adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Existing adalimumab formulation
Study: 19878390
Drug: Retin-OX+ lotion
Normalized name: tretinoin Topical Lotion [Retin-A]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retin-OX+ lotion applied on one side of the face for 8 weeks
Study: 15201246
Drug: Spironolactone 12.5‐50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 12.5‐50 mg/24 hours for three months
Study: 10914827
Drug: Anterior Resection
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior Resection (AR) for lower third rectal tumours
Study: 3582710
Drug: Hexyl nicotinate
Normalized name: Hexyl nicotinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexyl nicotinate lotion applied topically
Study: 30146421
Drug: 1 or
Normalized name: G-1 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 or more missed treatments in the 4 months before enrollment
Study: 30146421
Drug: Countries with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Countries with a 4-month missed treatment risk > 5%
Study: 30146421
Drug: Missed treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Missed treatments
Study: 20364681
Drug: Nitrosorbid (NS)
Normalized name: Dinitrosorbide
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrosorbid (NS) and hydrogen sulfide‐based balneotherapy (HSB) applied alone or in combination
Study: 20364681
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HSB and NS
Study: 15901766
Drug: Higher hemoglobin
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher hemoglobin target (13.5 to 14.5 g/dl)
Study: 15901766
Drug: Lower hemoglobin
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower hemoglobin target (9.5 to 11.5 g/dl)
Study: 8067231
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg morphine (intraarticular injection)
Study: 8067231
Drug: Saline (intraarticular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (intraarticular injection)
Study: 24044687
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei Shirota (LcS) probiotic drink, given once daily for the duration of the antibiotic course and continued for 7 days thereafter.
Study: 22289130
Drug: Medication (Fluoxetine)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Fluoxetine)
Study: 20053950
Drug: Treatment 3
Normalized name: Canesten Clotrimazole Thrush Treatment 3 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 3
Study: 20053950
Drug: Treatment 4
Normalized name: Acne Treatment 4 % - 5 % Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 4
Study: 16023710
Drug: Lidcombe Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidcombe Program (LP) treatment
Study: 16023710
Drug: Demands and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demands and Capacities Model (DCM) treatment
Study: 9082223
Drug: Intraperitoneal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal infusion of bupivacaine
Study: 9082223
Drug: Placebo (physiologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (physiologic solution)
Study: 6707202
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g protein/kg ideal body weight
Study: 6707202
Drug: 0.8 g
Normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g protein/kg ideal body weight plus 0.7 g carbohydrate/kg ideal body weight
Study: 26955678
Drug: WZR (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: WZR (oral administration)
Study: 20650361
Drug: Drug/device therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug/device therapies
Study: 11772264
Drug: Novel therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel therapies and vaccines for meningococcal disease
Study: 8488226
Drug: 5-session, time-limited
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-session, time-limited therapy (n = 16)
Study: 8488226
Drug: Time-unlimited therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-unlimited therapy (n = 15)
Study: 30256537
Drug: Rolapitant at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rolapitant at the highest safe dose (720 mg)
Study: 30256537
Drug: Rolapitant at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rolapitant at presumed therapeutic dose (180 mg)
Study: 20177420
Drug: Irinotecan and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan and 5-FU treatment in patients with ABCB1 3435 T/T genotype
Study: 20177420
Drug: Irinotecan and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan and 5-FU treatment in patients with UGT1A1(*)28/(*)28 genotype
Study: 20177420
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with toxicity during the first two cycles of treatment
Study: 19244090
Drug: Ethanol solution
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol solution (12.5%)
Study: 16516118
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of handheld FOB, misting, and end-tidal carbon dioxide concentration (ETCO2)
Study: 9419927
Drug: Preventive health
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive health care strategies (not specified dosage or duration)
Study: 9419927
Drug: Preventive Medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive Medicine profile
Study: 8487046
Drug: 12 g/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g/m2 MTX as a 4‐hour infusion (high-dose [HDM])
Study: 8487046
Drug: 1 g/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/m2 as a 36‐hour infusion (intermediate-dose [IDM])
Study: 3320181
Drug: Insulin 10
Normalized name: Human regular insulin 100 unit/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin 10 U and glucagon 1 mg in 500 ml 5% glucose in water via a peripheral vein for 2-6 h three times every day for 3 weeks
Study: 25360840
Drug: Xinxuekang (XXK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinxuekang (XXK) capsules
Study: 25360840
Drug: Compound Danshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Danshen (CDS) tablets
Study: 22104015
Drug: Everolimus and
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus and octreotide combination therapy for 12 months
Study: 16234004
Drug: Octreotide monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide monotherapy
Study: 16534006
Drug: Acetaminophen (frequent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (frequent use > or =22 d/mo)
Study: 16534006
Drug: NSAIDs (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (high dose > or =15 tablets per week)
Study: 16534006
Drug: Acetaminophen (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (high dose > or =15 tablets per week)
Study: 11569654
Drug: Cotrimoxazole (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole (single dose)
Study: 8482993
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg methylprednisolone acetate injected locally
Study: 3616850
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of erythromycin daily for a week
Study: 3616850
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of erythromycin daily for a week
Study: 22703532
Drug: Fludrocortisone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone 50 μg orally
Study: 22703532
Drug: Hydrocortisone 50
Normalized name: hydrocortisone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 50 mg intravenously
Study: 18094720
Drug: High-dose lipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose lipid formulation of amphotericin B (HD‐LPD/AMB)
Study: 11027806
Drug: Combined hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hepatitis A and B vaccine (HAB)
Study: 11027806
Drug: Concomitant hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant hepatitis A and B vaccines (HAV + HBV)
Study: 1610421
Drug: Domiodol 60
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Domiodol 60 mg t.i.d.
Study: 6369431
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg morphine intrathecally (spinal group)
Study: 6369431
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg body weight of morphine i.v. (i.V. group)
Study: 6369431
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg body weight epidurally (PDA group)
Study: 6369431
Drug: CSF morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSF morphine concentration 24 hrs after injection
Study: 30995657
Drug: HCO3 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCO3 (oral sodium bicarbonate)
Study: 30291483
Drug: 400-μg misoprostol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400-μg misoprostol rectally with 5-IU oxytocin IV
Study: 30291483
Drug: 400-μg misoprostol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400-μg misoprostol sublingually with 5-IU oxytocin IV
Study: 30291483
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between sublingual and rectal misoprostol
Study: 25800768
Drug: Early palliative
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early palliative care (PC) consultation, structured PC telehealth nurse coaching sessions (once per week for six sessions), and monthly follow-up
Study: 25800768
Drug: Delayed palliative
Normalized name: Various pain palliation radiopharmaceuticals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed palliative care (PC) consultation, structured PC telehealth nurse coaching sessions (once per week for six sessions), and monthly follow-up
Study: 31774584
Drug: Lorcaserin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin (20 mg)
Study: 21412231
Drug: Lorcaserin (supratherapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin (supratherapeutic doses)
Study: 21412231
Drug: Lorcaserin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin (all doses)
Study: 27253658
Drug: Zolpidem (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (15 and 30 mg)
Study: 19536092
Drug: Oxaliplatin and
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin and capecitabine treatment
Study: 9580448
Drug: Metamizol 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamizol 2 g
Study: 1778353
Drug: Active policy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active policy with either insulin or sulphonylurea aiming to reduce fasting plasma glucose to under 6 mmol/l
Study: 1778353
Drug: Tight control
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight control aiming for less than 150/85 mm Hg with either an angiotensin‐converting enzyme inhibitor or a Beta‐blocker
Study: 31927343
Drug: Observational cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observational cohort (OC) receiving oral standard of care
Study: 29228795
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A eye ointment (VAEO) administered every 6 hr for 5 days
Study: 26404953
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.5 μg calcitriol, 75 mg acetylsalicylic acid, and 1250 mg calcium carbonate (n = 209)
Study: 22537957
Drug: Ulinastatin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin treatment (1.0×10(4) U/kg)
Study: 19995589
Drug: Ethanol dehydration
Normalized name: Dehydrated ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol dehydration with 15s for each solution (Group 2)
Study: 18585508
Drug: Abciximab bolus
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab bolus + infusion (0.125 microg/[kg min] for 12 hours)
Study: 12121427
Drug: One daily
Normalized name: One Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: One daily bout of walking (Group S1)
Study: 12121427
Drug: Two daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two daily bouts of walking (Group S2)
Study: 10080677
Drug: Enteral Nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral Nutrition (EN) - 37 kcal/kg/day + 2.0 g proteins/kg/day for 34 days
Study: 10080677
Drug: Standard Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Oral Diet (SD)
Study: 2833577
Drug: Chemotherapy (VP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (VP and CAP combined)
Study: 24962635
Drug: Gemigliptin 50
Normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemigliptin 50 mg once daily for 6 days + Glimepiride 4 mg on day 7
Study: 24962635
Drug: Glimepiride 4
Normalized name: glimepiride 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 4 mg single dose
Study: 20524875
Drug: Glutathione, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutathione, 500 mg/day for 4 weeks
Study: 15824216
Drug: Verteporfin infusion
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin infusion with reduced fluence (RF) rate (300 mW/cm² for 83 seconds, light dose of 25 J/cm²)
Study: 15824216
Drug: Verteporfin infusion
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin infusion with standard fluence (SF) rate (600 mW/cm² for 83 seconds, light dose of 50 J/cm²)
Study: 12913718
Drug: Primary plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary plus booster immunizations (6 vaccine doses)
Study: 12913718
Drug: Primary immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary immunization (3 doses of vaccine)
Study: 8923161
Drug: Dexfenfluramine (dF)
Normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfenfluramine (dF) 15 mg bd
Study: 25340832
Drug: Retapamulin 1%
Normalized name: RETAPAMULIN 1% OINT,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retapamulin 1% ointment
Study: 22759797
Drug: Inhaled treprostinil
Normalized name: treprostinil Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled treprostinil (upper quartile of NT-proBNP)
Study: 20082236
Drug: LEF-anti-TNF-alpha combination
Normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEF-anti-TNF-alpha combination therapy
Study: 20082236
Drug: MTX-anti-TNF-alpha combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX-anti-TNF-alpha combination therapy
Study: 17587447
Drug: Chemotherapy (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (specific chemotherapy not detailed)
Study: 8521431
Drug: Acidulated phosphate
Normalized name: Acidulated Phosphate Fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acidulated phosphate fluoride (APF) gel
Study: 31148344
Drug: Pharmacists' beliefs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacists' beliefs about synthetic drugs
Study: 31148344
Drug: Pharmacists' beliefs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacists' beliefs about natural drugs
Study: 31148344
Drug: Pharmacists' opinions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacists' opinions on reporting adverse reactions of natural drugs
Study: 26536871
Drug: Paclitaxel (PTX)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (PTX) alone (80 mg/m², d1; n=47)
Study: 26536871
Drug: Iniparib plus
Normalized name: Iniparib
DrugBank: Iniparib (DB13877)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iniparib plus weekly Paclitaxel (PWI) (11.2 mg/kg, d1; n=46)
Study: 26536871
Drug: Iniparib plus
Normalized name: Iniparib
DrugBank: Iniparib (DB13877)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iniparib plus twice-weekly Paclitaxel (PTI) (5.6 mg/kg, d1, 4; n=48)
Study: 24400341
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training & Alagebrium (200 mg/day)
Study: 24400341
Drug: No exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: No exercise training & Alagebrium (200 mg/day)
Study: 16984235
Drug: rhIGF‐I/IGFBP‐3 complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I/IGFBP‐3 complex (SomatoKine) 0.4 mg/kg/day
Study: 15533733
Drug: Nifedipine coat-core
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine coat-core (20 mg once daily)
Study: 11579649
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rifampicin 600 mg plus ofloxacin 400 mg plus minocycline 100 mg (ROM) administered as single dose
Study: 8300461
Drug: Salbutamol inhaler
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol inhaler (100 mcg) 2 puffs tds
Study: 3572629
Drug: Formula B
Normalized name: Formula B
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula B (3.6 g/kg/d protein, 115 kcal/kg/d energy)
Study: 3572629
Drug: Formula C
Normalized name: Stress Formula Caplets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula C (3.5 g/kg/d protein, 149 kcal/kg/d energy)
Study: 3572629
Drug: Formula A
Normalized name: ACD-Solution Formula A
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formula A (2.24 g/kg/d protein, 113 kcal/kg/d energy)
Study: 24705232
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (0.2 mg) administered 2 hours before anesthesia
Study: 22760531
Drug: Delayed antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed antimicrobial treatment with amoxicillin‐clavulanate for 7 days
Study: 22760531
Drug: Immediate antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate antimicrobial treatment with amoxicillin‐clavulanate for 7 days
Study: 22760531
Drug: Delayed antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed antimicrobial treatment
Study: 10625579
Drug: Topical analgesia
Normalized name: ANALGESIC TOP GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical analgesia cream (EMLA)
Study: 10625579
Drug: Cooling (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooling (all treatments)
Study: 10625579
Drug: Pin-pricking (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pin-pricking (all treatments)
Study: 1536784
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with traditional Chinese medicinal plants for 8 weeks
Study: 6492228
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (10 g) with acetaminophen (1 g)
Study: 6492228
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (10 g) with sodium sulfate (18 g) and acetaminophen (1 g)
Study: 6492228
Drug: Sodium sulfate
Normalized name: Sodium Sulfate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium sulfate (18 g) with acetaminophen (1 g)
Study: 6492228
Drug: Acetaminophen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1 g) alone
Study: 19262392
Drug: Scalp block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalp block with 20 ml 0.5% bupivacaine
Study: 11915634
Drug: New injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: New injection system
Study: 9765767
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (160 mg 3 times daily for 10 days)
Study: 3057329
Drug: Bay 1099
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bay 1099 (25, 50, or 100 mg)
Study: 3057329
Drug: Bay 1099
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bay 1099 (50 mg tid)
Study: 28249150
Drug: Nemolizumab 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemolizumab 0.1 mg/kg every 4 weeks
Study: 28249150
Drug: Nemolizumab 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemolizumab 0.5 mg/kg every 4 weeks
Study: 28249150
Drug: Nemolizumab 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemolizumab 2.0 mg/kg every 4 weeks
Study: 23567902
Drug: WISE intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WISE intervention (motivational interviewing and cognitive behavioral therapy)
Study: 12040433
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with NA
Study: 2568643
Drug: procyclidine 5
Normalized name: procyclidine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: procyclidine 5 mg t.i.d.
Study: 2568643
Drug: promethazine 25
Normalized name: promethazine 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: promethazine 25 mg t.i.d.
Study: 2568643
Drug: haloperidol 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: haloperidol 4.5 mg t.i.d. (group HPL)
Study: 27899529
Drug: rTFA (2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTFA (2% of daily energy intake from ruminant TFA)
Study: 27899529
Drug: iTFA (2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: iTFA (2% of daily energy intake from industrial TFA)
Study: 22214714
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg, thrice a day) for 4 weeks